Discovery Paves Way for Pancreatic Cancer Treatment

Topic: Pancreatic Cancer
Author: University of Notre Dame
Published: 2016/11/12 - Updated: 2020/04/19
Contents: Summary - Introduction - Main Item - Related Topics

Synopsis: Patients with pancreatic cancer may soon face better treatment options due to a discovery by Dr. Reginald Hill, Archibald Assistant Professor of Cancer Biology. The bulk of a pancreatic cancer tumor is made of approximately 10 percent cancer cells and 90 percent supporting cells. Despite rising mortality rates, pancreatic cancer is under-researched and underfunded, and there are few approved treatments to combat the disease.

Introduction

Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.

Main Item

The five-year survival rate is only 8 percent, making it the only major cancer with a survival rate in the single digits. Despite rising mortality rates, pancreatic cancer is under-researched and underfunded, and there are few Food and Drug Administration-approved treatments to combat the disease.

With the current pipeline for drug discovery taking 10 to 15 years from the laboratory to use, and an estimated 41,780 who will die from the disease this year alone, time is of the essence.

Now, patients suffering from pancreatic cancer may soon face better treatment options due to the latest discovery by Dr. Reginald Hill, Archibald Assistant Professor of Cancer Biology at the University of Notre Dame and researcher at the Harper Cancer Research Institute. Hill's research focuses on drugs that are already approved by the FDA to find out why those drugs are not working in patients with pancreatic cancer.

"The bulk of a pancreatic cancer tumor is made of approximately 10 percent cancer cells and 90 percent supporting cells. Somehow, the supporting cells have figured out how to survive the chemotherapy," Hill said.

"Microscopic vesicles called exosomes, bubbles with genetic material released by cells during chemotherapy exposure, are released from supporting cells, educating the cancer cells on how to survive, resulting in a tumor becoming chemoresistant."

Research in the New England Journal of Medicine has revealed a majority of pancreatic cancer cases have proven to be resistant to chemotherapy and unresponsive to drug treatments found to be effective in other types of cancer.

Most new research has focused on destroying supportive cells. However, those studies concluded that when the supportive cells were attacked, patients actually developed more advanced cancer. "It was like poking holes into the area around the cancer cells and allowing it to spread," he said.

Hill focused on blocking the release of exosomes, preventing the relay of information from supporting cells to cancer cells - which increased the efficacy of chemotherapy. This recently published study suggests that using an exosome blocker, which is nontoxic, in combination with standard-of-care chemotherapy will those with pancreatic and many other cancers as well.

The lack of effective treatments available to help thousands of those with pancreatic cancer is what drew Hill to his research. This latest discovery paves the way for those patients to have greater hope.

The Harper Cancer Research Institute is how Notre Dame fights cancer. Located in South Bend, Indiana, its researchers are dedicated to conducting innovative and integrative research that confronts the complex challenges of cancer.

Attribution/Source(s):

This quality-reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by University of Notre Dame, and published on 2016/11/12 (Edit Update: 2020/04/19), the content may have been edited for style, clarity, or brevity. For further details or clarifications, University of Notre Dame can be contacted at harpercancer.nd.edu. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Related Topics

1 - - A clinical trial will examine if chemotherapy followed by a novel surgical procedure can improve outcomes for patients with pancreatic tumors previously considered inoperable.

2 - - Study reveals the details of two key transition points in the development of pancreatic cancer and provides insights into treatment resistance and how immunotherapy could be used to treat this tumor type.

3 - - New study shows that stress accelerates the development of pancreatic cancer by triggering the release of fight or flight hormones.

4 - - Patients with pancreatic cancer may soon face better treatment options due to a discovery by Dr. Reginald Hill, Archibald Assistant Professor of Cancer Biology.

5 - - Clinical trial for pancreatic cancer shows experimental therapy can control tumors enough to make some patients eligible for surgery.

Complete List of Related Information

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): University of Notre Dame. (2016, November 12 - Last revised: 2020, April 19). Discovery Paves Way for Pancreatic Cancer Treatment. Disabled World. Retrieved October 16, 2024 from www.disabled-world.com/health/cancer/pancreatic/pc-exosomes.php

Permalink: <a href="https://www.disabled-world.com/health/cancer/pancreatic/pc-exosomes.php">Discovery Paves Way for Pancreatic Cancer Treatment</a>: Patients with pancreatic cancer may soon face better treatment options due to a discovery by Dr. Reginald Hill, Archibald Assistant Professor of Cancer Biology.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.